Therapeutic approaches in patients with newly diagnosed follicular lymphoma.

Abstract

The prognosis of follicular lymphoma (FL) has significantly improved over the last decade, particularly following the introduction of the anti-CD20 monoclonal antibody rituximab, which has challenged the old concept of FL as an incurable disease. However, the decision whether to start treatment in a patient with advanced FL or adopt a watch-and-wait policy remains a subject of controversy. Furthermore, the optimal first-line treatment for FL remains a clinical challenge owing to the numerous different therapeutic options available. In this review, the authors focus on the initial management of patients with newly diagnosed FL, consider the different treatment options for every stage, paying special consideration to the therapeutic approaches for each clinical scenario, and discuss future directions.

• Authors: David Aguiar-Bujanda, María Jesús Blanco-Sánchez, Pedro Jiménez-Gallego, Marta Mori-De Santiago, María Hernández-Sosa, Saray Galván-Ruíz, Samuel Hernández-Sarmiento, Salvador Saura-Grau, Uriel Bohn-Sarmiento
• Journal: Future oncology (London, England) (Future Oncol) Vol. 10 Issue 12 Pg. 1967-80 (Oct 2014) ISSN: 1744-8301 [Electronic] England
• PMID: 25386813 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't, Review)

Topics

• Clinical Trials as Topic
• Humans
• Lymphoma, Follicular (therapy)